OTSUKA-PHARMACEUTICAL
- Establishment of the new company will further support Otsuka's rapid growth in Europe which has been more than two-fold over the past 5 years.
- The European market comprises 25%* of the total global pharmaceutical market making a strong European presence in clinical drug development essential.
- Otsuka Europe Development and Commercialisation Ltd. is Otsuka's 9 th research and development institute.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the formation of Otsuka Europe Development and Commercialisation Ltd. (OEDC).
Established on July 1st , 2013, OEDC is an important milestone for Otsuka's growing European pharmaceutical business and a significant long-term investment for Otsuka in Europe. OEDC will be Otsuka's European Research and Development Headquarters, working alongside Otsuka Pharmaceutical Europe Ltd (OPEL) to ensure the successful development and commercialisation of our products.
"We are delighted to establish this new company in the UK," said Dean Haubrich, President and CEO of OEDC. "We believe that Otsuka has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence."
OEDC and OPEL are separate entities based in the same location, just outside London. This business model allows for optimal collaboration and is a critical success factor in the evolution of our global business. Our research and development and commercial operations teams will work closely together, with aligned goals, to build one fully integrated European company which will enable us to effectively respond to the increasingly rigorous regulatory environment.
"The opening of OEDC is a very important milestone for Otsuka in Europe," said Ole Vahlgren, President and CEO of OPEL "This significant long-term investment will strengthen Otsuka Europe's continued efforts to bring Otsuka's innovative medicines to patients across Europe."
* (C)2013 IMSHealth. Calculated based on IMS World Review 2013 (Executive Summary) Reprinted with permission
|
About Otsuka Europe Development & Commercialisation Ltd. |
||
|
Company Name: |
Otsuka Europe Development and Commercialisation Ltd. | |
|
Date of Foundation: |
1st July 2013 | |
|
Capital: |
€1 million | |
|
CEO & President: |
Dean Haubrich | |
|
Head Office: |
Hunton House, Highbridge Estate, Oxford Road, Uxbridge, Middlesex, UB8 1LX, United Kingdom | |
|
Scope of Business: |
Research and Development | |
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and for several decades has been active in research on tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately USD13 billion or €10 billion for fiscal year 2012 (4/1/2012-3/31/2013). Otsuka welcomes you to visit its global website at https://www.otsuka.co.jp/en
Contact:
Otsuka media contacts
Europe:
Otsuka
Pharmaceutical Europe Ltd.
Alison Ross, +44-(0)-1895-207122,
+44-(0)-7768-337128 (m)
aross@otsuka-europe.com
or
Japan:
Otsuka
Pharmaceutical Co., Ltd.
Jeffrey Gilbert, +81-3-6361-7379,
+81-80-8728-6039 (m)
gilbert.jeffrey@otsuka.jp
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 21:00:00 CEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 15:00:00 CEST | Press release
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partne
Qualcomm Announces Quarterly Cash Dividend18.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
MultiBank Group Confirms $MBG Token Listings on MEXC and Gate.io on TGE Day in Addition to MultiBank.io and Uniswap18.7.2025 14:34:00 CEST | Press release
MultiBank Group, the world’s largest & most regulated financial derivatives institution, is proud to announce that its highly anticipated $MBG Token will be listed on two new major global cryptocurrency exchanges — MEXC and Gate.io — on the day of its official Token Generation Event (TGE), July 22, 2025, in addition to MultiBank.io and Uniswap. The $MBG Token will go live on: MultiBank.ioGate.ioMEXCUniswap This new dual listing will allow millions of users across both exchanges to seamlessly access and trade $MBG using their existing accounts, ensuring immediate market participation at launch. The Token Generation Event (TGE) is now approaching following the successful completion of two pre-sale rounds, where MultiBank Group issued 7 million tokens in Round 1 and 3 million tokens in Round 2 — both of which sold out within minutes. Naser Taher, Chairman and Founder of MultiBank Group said “With $MBG, we’re introducing a utility token built to deliver real-world value, transparency, and
SLB Announces Second-Quarter 2025 Results18.7.2025 12:50:00 CEST | Press release
Revenue of $8.55 billion increased 1% sequentially and decreased 6% year on year GAAP EPS of $0.74 increased 28% sequentially and decreased 4% year on year EPS, excluding charges and credits, of $0.74 increased 3% sequentially and decreased 13% year on year Net income attributable to SLB of $1.01 billion increased 27% sequentially and decreased 9% year on year Adjusted EBITDA of $2.05 billion increased 2% sequentially and decreased 10% year on year Cash flow from operations was $1.14 billion and free cash flow was $622 million Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the second-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716727689/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2025Mar. 31, 2025Jun. 30, 2024SequentialYear-on-yearReve
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum